Now I have read the full paper. Let me produce the updated review based on verifying the rebuttal claims against the actual paper content.

---

## Summary

The paper evaluates small language models (SLMs, ≤3B) and small vision-language models against medically adapted large counterparts (7–9B) on consumer health question summarization (MeQSum) and radiology report generation (MIMIC-CXR). It introduces a "Collapse Analysis" framework (Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, and a composite Readiness Score) and claims LoRA-fine-tuned SLMs can match or exceed large medical LLMs on summarization, while a "safety collapse" occurs at sub-1B scales, and small VLMs still lag behind large VLMs for radiology.

---

## Rebuttal Assessment

### Weakness 1: Asymmetric comparison — fine-tuning only applied to small models
- **Author's response:** Partially address
- **Assessment:** Partially convincing — The author argues the asymmetry is deliberate: large models evaluated under their "intended deployment form" (domain pretraining via ICL) versus SLMs fine-tuned with LoRA. They cite Section 2's statement that SLMs are positioned "as efficient solutions for context-grounded information extraction, rather than open-ended clinical reasoning." This framing is present in the paper but is buried in Related Work; it does not appear in the Results or Discussion as a caveat on the headline claim. Section 4 still states plainly: *"After LoRA fine-tuning, all small LMs outperformed large LMs across every metric"* — with no qualifier that large models were evaluated only in their ICL configuration. The promised revision to add this qualifier does not exist in the current manuscript. The comparison remains asymmetric, the headline claim remains unqualified, and the author's promised fix is not yet in the paper. The rebuttal offers a legitimate conceptual reframing but does not repair the as-submitted paper.
- **Score impact:** Weakness downgraded (from central fatal flaw to major methodological limitation with a legitimate but unstated design rationale)

---

### Weakness 2: Collapse Analysis framework lacks measurement protocol
- **Author's response:** Partially address
- **Assessment:** Unconvincing — The author claims partial grounding exists in Section 3.1, citing the hallucination rate analysis as attributed to "Li et al., 2024a." I verified this: Section 3.1 does mention hallucination rates and cites Li et al. 2024a, but the paper provides zero definition of how Task Adherence, Concept Recall, or Prompt Robustness are computed, and zero formula for the Readiness Score. The citation to Li et al. 2024a for hallucination rates is a literature reference, not a measurement protocol. The promised supplementary appendix does not exist in the submitted paper. Table 3's precise numeric values (e.g., SmolLM2-135M Task Adherence = 0.23, Readiness Score = 0.19) remain entirely unverifiable assertions. This is the paper's most distinctive contribution and it is operationally undefined.
- **Score impact:** Weakness unchanged

---

### Weakness 3: Internal contradiction in VLM results
- **Author's response:** Acknowledge
- **Assessment:** Partially convincing — The author correctly acknowledges that Section 3.3's claim that "both small VLMs remain below the large VLM baselines in all metrics" is factually wrong per Table 4 (Qwen2.5-VL BERTScore: 0.8146 vs. Med-Flamingo: 0.7100, LLaVA-Med: 0.6850). The author's metric-level explanation is reasonable: BERTScore captures surface semantic similarity, while BLEU, ROUGE-L, and MEDCON better capture structural and clinical concept fidelity. However, I note that the contradiction extends beyond Section 3.3: Section 5's Discussion (line 249) also states "yet still fell short of large VLM baselines (Med-Flamingo, LLaVA-Med) on all metrics (Table 4)" — which is equally wrong. The rebuttal acknowledges only the Section 3.3 instance. Furthermore, Finding 2 and the Abstract both state that "small VLMs consistently lag behind larger counterparts" without qualification. The BERTScore reversal is non-trivial and the paper's characterization is not just imprecise but factually incorrect in multiple places. Promised revision does not appear in the current manuscript.
- **Score impact:** Weakness unchanged (contradiction is more pervasive than author acknowledges)

---

### Weakness 4: ~1B safety threshold overstated
- **Author's response:** Partially address
- **Assessment:** Partially convincing — The author acknowledges the sparse data points and cross-family inconsistency. The rebuttal's reframing — that the key observation is the discontinuous jump (2–3% → 18–75%), not the precise 1B threshold — is reasonable as a conceptual defense. However, Table 3's caption still reads "We identify a safety threshold at approximately 1B parameters," and no revision to characterize it as "roughly 360M–1B" exists in the submitted text. The cross-family inconsistency (Gemma-3-1B already at Task Adherence 0.70 vs. SmolLM2-1.7B at 0.95) is acknowledged but not explained.
- **Score impact:** Weakness downgraded (from overstated claim to acknowledged precision limitation)

---

### Weakness 5: Broken cross-reference ("Table ??")
- **Author's response:** Acknowledge
- **Assessment:** Unconvincing as a rebuttal defense — The author acknowledges the error and identifies the intended referent as Table 4. This is correct (Table 4 appears at line 253–262 of the paper). However, acknowledging a manuscript preparation error that signals an incomplete submission does not remove the weakness. The broken reference (line 219: "From Table ?? we can infer…") remains in the submitted paper.
- **Score impact:** Weakness unchanged

---

### Weakness 6: Decoding strategy ambiguity
- **Author's response:** Partially address
- **Assessment:** Partially convincing — The author claims the intention was to average across three decoding strategies for all models uniformly. However, I note a deeper issue: the paper describes top-k=3, top-p=0.9, and temperature=0.3 as three separate "stochastic decoding strategies," yet averaging results across qualitatively different sampling schemes is methodologically unusual and introduces its own confound. The paper says "All runs employ identical inference settings" at line 76, but then lists three distinct strategies at line 78 — these statements are in tension. Averaging across them is not explained or justified. The promised clarification does not appear in the current paper.
- **Score impact:** Weakness unchanged

---

### Weakness 7: No confidence intervals or significance testing
- **Author's response:** Acknowledge
- **Assessment:** Honest acknowledgment — The author fully acknowledges that the 250-sample test set makes small metric differences non-significant without variance reporting. The promise to add bootstrap CIs in revision is appropriate but does not address the as-submitted paper. Results like SmolLM2-1.7B BERTScore 0.9007 vs. OpenBioLLM-8B 0.8938 (Table 2) continue to be presented as meaningful without error bars.
- **Score impact:** Weakness unchanged

---

### Weakness 8: SmolLM2 hallucination instability understated
- **Author's response:** Acknowledge
- **Assessment:** Honest but doesn't fix the problem — The author correctly distinguishes that the parenthetical "occasionally led to hallucinations in extreme cases" in Section 4 refers to the fine-tuned SmolLM2-1.7B, not to the sub-360M models. This contextual clarification is plausible but not supported in the actual text of Section 4, which doesn't specify which SmolLM2 variant it refers to. Table 3 shows 67.8% hallucination for SmolLM2-135M and 18.3% for SmolLM2-360M — these numbers are simply not reconcilable with "occasional" without the clarification the author promises to add.
- **Score impact:** Weakness unchanged

---

## Strengths

- **Clinically motivated multi-family scaling analysis**: Evaluation spans SmolLM2 (135M–3B), Gemma-3 (270M–4B), and LLaMA-3.2 across two tasks and two modalities, providing a cross-family view of degradation with scale (Table 3).
- **"Safety collapse" framing is conceptually useful**: The observed discontinuous jump from ~2–3% hallucination rates at ≥1.7B to 18.3% (SmolLM2-360M) and 75% (Gemma-3-270M) — even if unverifiable in measurement protocol — provides a practically meaningful cliff-like signal rather than a smooth scaling curve.
- **Both adaptation strategies tested for SLMs**: Zero-shot, few-shot ICL, LoRA, QLoRA, and prompt tuning are all applied to the SLM side, providing a structured comparison (Section 3.2, Figure 3).

---

## Weaknesses

### Fatal
*None individually fatal, but the major issues collectively undermine the primary claims and the paper's most distinctive contribution.*

### Major

- **Asymmetric comparison invalidates the headline claim (partially mitigated by rebuttal).** The paper's headline finding — "After LoRA fine-tuning, all small LMs outperformed large LMs across every metric" — rests on fine-tuning only the small models. The rebuttal's design rationale (large models tested under their intended deployment form) is legitimate but is not stated clearly in the paper. The claim in Section 4 and Section 5 is not qualified, and the promised qualification revision does not exist in the submitted text. The comparison cannot distinguish "small models are sufficient" from "fine-tuning matters more than scale."

- **Collapse Analysis framework entirely undefined.** Table 3 presents precise values for Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, and Readiness Score, with no measurement protocol for any of them. Citing Li et al. 2024a for hallucination rates is a literature reference, not a methodology definition. The Readiness Score formula does not appear anywhere in the paper. The promised supplementary appendix is not in the submitted manuscript. The paper's signature contribution is operationally unverifiable.

- **VLM contradiction more pervasive than author acknowledges.** Table 4 shows Qwen2.5-VL BERTScore 0.8146 > Med-Flamingo 0.7100 and LLaVA-Med 0.6850. The paper contradicts this in Section 3.3 ("both small VLMs remain below the large VLM baselines in all metrics"), Section 5 Discussion (line 249: "yet still fell short of large VLM baselines…on all metrics (Table 4)"), and the Abstract. The rebuttal only acknowledged the Section 3.3 instance. None of the contradictions are corrected in the submitted paper.

### Minor

- **Safety threshold stated more precisely than the data support.** Table 3 caption still reads "safety threshold at approximately 1B parameters" despite the SmolLM2 family having no measurements between 360M and 1.7B, and the Gemma-3 family showing degradation even at 1B. Rebuttal acknowledges this but revision is not in submitted paper.
- **Decoding strategy ambiguity.** Three distinct sampling strategies described but it is not stated whether results are averaged or how this averaging is implemented. Averaging across qualitatively different decoding schemes is itself methodologically unusual.
- **No confidence intervals.** With n=250, margin differences such as SmolLM2 BERTScore 0.9007 vs. OpenBioLLM 0.8938 are not statistically testable as presented. No bootstrapped CIs or significance tests appear anywhere.
- **Broken cross-reference.** "From Table ?? we can infer…" at line 219 remains unresolved in the submitted paper.

### Trivial

- SmolLM2 hallucination rate of 67.8% (SmolLM2-135M) and 18.3% (SmolLM2-360M) is described only as "occasionally led to hallucinations in extreme cases" in Section 4 — severe understatement of what Table 3 shows, even accounting for the rebuttal's contextual explanation.

---

## Nice-to-Haves

- Fine-tune at least BioMistral-7B with LoRA on MeQSum; if fine-tuned SLMs still outperform fine-tuned large LLMs, the efficiency case strengthens significantly.
- Publish the Collapse Analysis protocol as a supplementary appendix with annotation rubric, hallucination detection code/procedure, and the Readiness Score formula.
- Add intermediate model sizes (500M–800M) to sharpen the threshold estimate.
- Reconcile the BERTScore VLM reversal explicitly throughout all sections that currently claim "all metrics."

---

## Novel Insights

The most genuinely novel observation — that hallucination degradation below ~1B parameters is discontinuous (a cliff rather than a slope) — remains conceptually interesting even if unverifiable as currently presented. The cross-family data showing that two different model families both exhibit this cliff (SmolLM2-360M: 18.3%, Gemma-3-270M: 75% vs. ≤3.5% above 1.7B) strengthens the claim against family-specific artifacts. If the Collapse Analysis metrics were operationally defined and reproducible, this observation would be genuinely actionable for deployment decisions. The rebuttal does not strengthen the novelty claim since it provides no new evidence; it merely recontextualizes existing (unverifiable) numbers.

---

## Suggestions

1. Add a LoRA-tuned BioMistral-7B baseline to Figure 3 to test whether scale or adaptation drives the performance gap.
2. Publish the full Collapse Analysis protocol, including hallucination detection methodology, Task Adherence rubric, and Readiness Score formula, as a supplementary appendix.
3. Revise all four instances where the paper claims small VLMs lag "in all metrics" to acknowledge the BERTScore reversal and offer a principled explanation.
4. Add bootstrap confidence intervals (n=1,000) to all metric comparisons in Tables 2 and 4.
5. Fix the broken "Table ??" reference in Section 3.3, and qualify the Section 4 headline claim to specify the comparison is between LoRA-fine-tuned SLMs and ICL-configured large LLMs.

---

## Score and Decision

**Rebuttal impact on assessment:**

The rebuttal is overwhelmingly a series of honest acknowledgments with promises to revise — none of which exist in the submitted paper. Per the evaluation guidelines, "a rebuttal that says 'we will add this in the revision' does not count as addressing the weakness." Only one weakness received partial credit for providing existing paper evidence: the asymmetric comparison has a legitimate design rationale grounded in Section 2, though it is not sufficiently foregrounded in the submitted text to qualify the headline claim. 

The VLM contradiction is actually *more* pervasive than the review originally noted — the rebuttal revealed that the author only acknowledged one of three instances where the paper incorrectly states small VLMs lag "in all metrics." The Collapse Analysis remains entirely unverifiable. The broken reference, missing CIs, and decoding ambiguity all persist unchanged.

The rebuttal does not provide new evidence, new experiments, or any actual revisions. It primarily demonstrates that the authors understand their paper's weaknesses, which is credit for intellectual honesty but not for scientific contribution.

**Final assessment:** The paper sits at the boundary of the 3.0 anchor papers (KG benchmarking, EchoQA) rejected for undefined methodology and limited rigor. The rebuttal partially upgrades one major weakness and provides helpful context on VLM metric nuance, but does not change the fundamental problems: an asymmetric headline comparison, an operationally undefined core contribution, multiple internal contradictions, and no statistical validation. Marginal upward adjustment from the rebuttal's honest engagement, but the paper remains below the threshold for acceptance.

**Score: 3.0** — maintained. The rebuttal's honest acknowledgments and one partial defense of the asymmetric comparison design rationale are insufficient to move the score meaningfully upward.

MY FINAL SCORE: <score>3.0</score>
MY FINAL DECISION: <decision>Reject</decision>